These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 23726875)

  • 1. Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus.
    Aghemo A; Colombo M
    Gastroenterology; 2013 Jul; 145(1):247-249. PubMed ID: 23726875
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon free regimens for the "difficult-to-treat": are we there?
    Londoño MC; Lens S; Forns X
    J Hepatol; 2013 Apr; 58(4):643-5. PubMed ID: 23333449
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral Direct Acting Antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype.
    Lee SW; Yang SS; Lee TY; Yeh HZ; Lu IT; Chang CS
    J Gastrointestin Liver Dis; 2017 Jun; 26(2):205-206. PubMed ID: 28617895
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
    Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
    J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
    Hassanein T; Sims KD; Bennett M; Gitlin N; Lawitz E; Nguyen T; Webster L; Younossi Z; Schwartz H; Thuluvath PJ; Zhou H; Rege B; McPhee F; Zhou N; Wind-Rotolo M; Chung E; Griffies A; Grasela DM; Gardiner DF
    J Hepatol; 2015 May; 62(5):1204-6. PubMed ID: 25559328
    [No Abstract]   [Full Text] [Related]  

  • 6. Continued progress against hepatitis C infection.
    Conjeevaram H
    JAMA; 2015 May; 313(17):1716-7. PubMed ID: 25942721
    [No Abstract]   [Full Text] [Related]  

  • 7. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction.
    Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Goto H; Hirooka Y
    Clin Gastroenterol Hepatol; 2017 May; 15(5):787-788. PubMed ID: 28013118
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
    Miyazaki R; Miyagi K
    Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
    Thiam A; Conway B
    Drugs Today (Barc); 2018 Apr; 54(4):237-244. PubMed ID: 29869645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.
    Chayama K; Hayes CN
    J Gastroenterol; 2017 Jan; 52(1):125-126. PubMed ID: 27541041
    [No Abstract]   [Full Text] [Related]  

  • 12. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
    Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
    JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
    Jensen D; Sherman KE; Hézode C; Pol S; Zeuzem S; de Ledinghen V; Tran A; Elkhashab M; Younes ZH; Kugelmas M; Mauss S; Everson G; Luketic V; Vierling J; Serfaty L; Brunetto M; Heo J; Bernstein D; McPhee F; Hennicken D; Mendez P; Hughes E; Noviello S;
    J Hepatol; 2015 Jul; 63(1):30-7. PubMed ID: 25703086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
    Poordad F; Sievert W; Mollison L; Bennett M; Tse E; Bräu N; Levin J; Sepe T; Lee SS; Angus P; Conway B; Pol S; Boyer N; Bronowicki JP; Jacobson I; Muir AJ; Reddy KR; Tam E; Ortiz-Lasanta G; de Lédinghen V; Sulkowski M; Boparai N; McPhee F; Hughes E; Swenson ES; Yin PD;
    JAMA; 2015 May; 313(17):1728-35. PubMed ID: 25942723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
    Ishigami M; Hayashi K; Honda T; Kuzuya T; Ishizu Y; Ishikawa T; Nakano I; Urano F; Kumada T; Yoshioka K; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2017 Nov; 32(11):1879-1886. PubMed ID: 28258705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
    Signorovitch JE; Betts KA; Song Y; Sorg RA; Li J; Behl AS; Kalsekar A
    J Comp Eff Res; 2015 Nov; 4(6):593-605. PubMed ID: 26159375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.
    Kao JH; Yu ML; Peng CY; Heo J; Chu CJ; Chang TT; Lee YJ; Hu TH; Yoon KT; Paik SW; Lim YS; Ahn SH; Isakov V; McPhee F; Hu W; Scott Swenson E; Yin PD; Treitel M
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1998-2005. PubMed ID: 28370350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
    Liu Y; Wang Z; Tobe RG; Lin H; Wu B
    Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.